Chao Liu

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

Chao Liu, Ruiqi Liu, Bojun Wang et al. · Journal for ImmunoTherapy of Cancer · 2021 · 248 citations · Full text

Medicine, Immunology, Oncology +17

Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer

Huimin Meng, Ping Zheng, Xiaoyan Wang et al. · Cancer Biology & Therapy · 2010 · 221 citations

Medicine, Cancer Biology, Oncology +17

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation–Associated Advanced Ovarian Cancer

Sanjeeve Balasubramaniam, Julia A. Beaver, Sara Horton et al. · Clinical Cancer Research · 2017 · 164 citations

Medicine, Gynecology, Oncology +17

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Hongshan Li, Jingyu Yu, Chao Liu et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 138 citations

Pharmacy, Oncology, Pharmacokinetics +11